Announcement: Regulatory Agencies Split on New Alzheimer’s Drugs as Hope Meets Uncertainty

GMJ
By
Prof. Giorgi Pkhakadze
0 Min Read
Regulatory agencies reviewing Alzheimer's disease treatment approvals with conflicting decisions
Regulatory agencies worldwide are delivering conflicting assessments of novel Alzheimer's treatments, creating uncertainty for millions of patients. The Lancet examines divergent approval pathways and their implications for global access. — Photo: SHVETS production / Pexels
1 min read|40 words

Breaking: Global regulatory agencies are reaching conflicting decisions on new Alzheimer's treatments, creating unprecedented disparities in patient access worldwide. The Lancet examines why breakthrough drugs face such different approval pathways across countries.

Read the full article on GMJ Newsroom →

Was this article helpful?

Share This Article
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Taurine and Cancer: Separating Laboratory Findings from Dietary Risk

Recent headlines claimed taurine fuels cancer, but a Nature study of leukemia…

Sleep deprivation damages multiple body systems simultaneously, six controlled studies show

Six controlled studies show that sleep deprivation simultaneously disrupts hormonal regulation, metabolic…

How Vitamins and Minerals Power Brain Chemistry: The Neurotransmitter Connection

Vitamins B6, B12, folate, and minerals including zinc, magnesium, and iron function…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like